StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Interpace Biosciences's operating income for the twelve months ending Jun 30, 2026 was $4.17M, down 27.2% year over year. For fiscal 2025 it was $4.08M, down 49.6% from the year before. The highest annual figure on record is $8.11M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.08M-49.6%
FY2024Dec 31, 2024$8.11M+105.0%
FY2023Dec 31, 2023$3.96M–
FY2022Dec 31, 2022-$3.62M–
FY2021Dec 31, 2021-$6.34M–
FY2020Dec 31, 2020-$26.07M–
FY2019Dec 31, 2019-$26.44M–
FY2018Dec 31, 2018-$12.63M–
FY2017Dec 31, 2017-$6.29M–
FY2016Dec 31, 2016-$6.44M–
FY2015Dec 31, 2015-$40.41M–
FY2014Dec 31, 2014-$17.83M–
FY2013Dec 31, 2013-$1.44M–
FY2012Dec 31, 2012-$25.23M–
FY2011Dec 31, 2011-$4.70M–
FY2010Dec 31, 2010-$6.90M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$321.00K–
Q1 FY2026Mar 31, 2026$1.12M-38.6%
Q4 FY2025Dec 31, 2025$1.58M-23.5%
Q3 FY2025Sep 30, 2025$1.15M-50.2%
Q2 FY2025Jun 30, 2025-$468.00K-117.8%
Q1 FY2025Mar 31, 2025$1.83M+64.2%
Q4 FY2024Dec 31, 2024$2.06M+38.3%
Q3 FY2024Sep 30, 2024$2.30M+458.5%
Q2 FY2024Jun 30, 2024$2.63M+116.4%
Q1 FY2024Mar 31, 2024$1.11M+32.9%
Q4 FY2023Dec 31, 2023$1.49M+2659.3%
Q3 FY2023Sep 30, 2023$412.00K–
Q2 FY2023Jun 30, 2023$1.22M–
Q1 FY2023Mar 31, 2023$838.00K–
Q4 FY2022Dec 31, 2022$54.00K–
Q3 FY2022Sep 30, 2022-$780.00K–
Q2 FY2022Jun 30, 2022-$1.91M–
Q1 FY2022Mar 31, 2022-$977.00K–
Q4 FY2021Dec 31, 2021-$1.35M–
Q3 FY2021Sep 30, 2021-$1.83M–
Q2 FY2021Jun 30, 2021-$2.91M–
Q1 FY2021Mar 31, 2021-$3.82M–
Q4 FY2020Dec 31, 2020-$7.94M–
Q3 FY2020Sep 30, 2020-$6.01M–
Q2 FY2020Jun 30, 2020-$5.77M–
Q1 FY2020Mar 31, 2020-$6.35M–
Q4 FY2019Dec 31, 2019-$10.77M–
Q3 FY2019Sep 30, 2019-$7.13M–
Q2 FY2019Jun 30, 2019-$5.35M–
Q1 FY2019Mar 31, 2019-$3.18M–
Q4 FY2018Dec 31, 2018-$5.02M–
Q3 FY2018Sep 30, 2018-$2.47M–
Q2 FY2018Jun 30, 2018-$1.90M–
Q1 FY2018Mar 31, 2018-$3.25M-187.8%
Q4 FY2017Dec 31, 2017-$3.30M-148.9%
Q3 FY2017Sep 30, 2017-$3.10M–
Q2 FY2017Jun 30, 2017-$3.60M–
Q1 FY2017Mar 31, 2017$3.70M–
Q4 FY2016Dec 31, 2016$6.74M–
Q3 FY2016Sep 30, 2016-$6.49M–

More Interpace Biosciences figures

See a number that looks wrong?